No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Liraglutide’s cardiovascular safety profile gets support from a majority of an FDA advisory committee, but a preclinical thyroid cancer risk results in a tied vote on the approvability of Novo Nordisk’s type 2 diabetes drug.
You may also be interested in...
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.